Pharmacologic Profile and Therapeutic Potential of NCX 4016, a Nitric Oxide‐releasing Aspirin, for Cardiovascular Disorders
Authors:
- 1 June 2006
- journal article
- review article
- Published by Wiley in Cardiovascular Drug Reviews
- Vol. 24 (2) , 148-168
Abstract
NCX 4016, 2‐(acetyloxy)benzoic acid 3‐[(nitrooxy)methyl]phenyl ester, is a new molecule in which a nitric oxide (NO)‐releasing moiety is covalently linked to aspirin. After enzymatic metabolism, NCX 4016 releases both components.In vitroand in some animal models, these components exert their pharmacologic effects simultaneously. Nitric oxide (NO) is a small gaseous molecule that exerts several activities which may prevent atherothrombotic disorders. Moreover, it displays a protective activity on the gastric mucosa.NCX 4016 has been shown to inhibit platelet activationin vitromore effectively than aspirin, to inhibit smooth muscle cell proliferation, to exert an endothelial cell protective activity and to suppress the function of several inflammatory cells potentially involved in atherothrombosis.In animal models, NCX 4016 protected from platelet thromboembolism, prevented restenosis in atherosclerosis‐prone animals, protected the heart from ischemia/reperfusion injury, and induced neoangiogenesis in critically ischemic limbs. Moreover, it displayed little or no gastric toxicity and appeared to protect stomach from noxious stimuli, including aspirin.NCX 4016 has been evaluated in healthy volunteers and found to inhibit platelet cyclo‐oxygenase‐1 (COX‐1) similarly to or slightly less than aspirin, to raise the circulating levels of NO‐degradation products, and to have little or no gastric toxicity in short term studies. In particular, in phase II studies, NCX 4016 had favorable effects on effort‐induced endothelial dysfunction in intermittent claudication and on platelet‐activation parameters elicited by short‐term hyperglycemia in type II diabetics. In patients with type II diabetes the effects of NCX 4016 on microalbuminuria and on some hemodynamic parameters were promising. The pharmacokinetics ofin vivoaspirin‐ and NO‐ released by NCX 4016, as well as the bioavailability of the two molecules, were not yet adequately studied. Also, the long‐term tolerability of NCX 4016, as well as its possible effectiveness in preventing ischemic cardiovascular events and progression of atherosclerosis, should be explored.Keywords
This publication has 88 references indexed in Scilit:
- Inflammation and insulin resistanceJournal of Clinical Investigation, 2006
- Nitroaspirins and Morpholinosydnonimine but Not Aspirin Inhibit the Formation of Superoxide and the Expression of gp91 phox Induced by Endotoxin and Cytokines in Pig Pulmonary Artery Vascular Smooth Muscle Cells and Endothelial CellsCirculation, 2004
- Nitric oxide release and distribution following oral and intraperitoneal administration of nitroaspirin (NCX 4016) in the ratLife Sciences, 2004
- Chemiluminescence and LC–MS/MS analyses for the study of nitric oxide release and distribution following oral administration of nitroaspirin (NCX 4016) in healthy volunteersJournal of Pharmaceutical and Biomedical Analysis, 2004
- Aspirin, but not NO-releasing aspirin (NCX-4016), interacts with selective COX-2 inhibitors to aggravate gastric damage and inflammationAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2004
- NCX4016 (NO‐aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigsBritish Journal of Pharmacology, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002
- A Common Pathway for Nitric Oxide Release from NO–Aspirin and Glyceryl TrinitrateBiochemical and Biophysical Research Communications, 2000
- Pharmacokinetics of a new nitroderivative of acetylsalicylic acid after a single dose in ratsLife Sciences, 1996
- Effect of single and repeated doses of a new nitroderivative of acetylsalicylic acid on platelet TXA2 production in ratsLife Sciences, 1996